1405-9940 1405-9940 S1405-99402023000600014 10.24875/acm.23000059 Panamá Colombia Honduras Costa Rica Venezuela Paraguay Ecuador Ecuador Perú Nicaragua México Colombia 00 00 2023 00 00 2023 93 14 26

1 2007 93 1137-46 2 2016 133 e38-e360 3 2013 113 646-59 4 2013 62 949-58 5 2020 1-7 6 World Health Organization 1998 7 2018 35 70-6 8 2018 7 97-104 9 The SIGMA (Slim Initiative in Genomic Medicine for the Americas) Type 2 Diabetes Consortium 2014 506 97-101 10 2017 101-26 11 2019 35 12 1974 34 29-34 13 2005 28 612-6 14 2001 161 996-1002 15 2015 132 923-31 16 2013 15 194-202 17 2000 21 1368-75 18 2003 107 1291-6 19 2013 167 1206-16 20 2009 6 89-94 21 2009 53 747-53 22 1994 15 1528-32 23 2000 26 (Suppl 3) (Suppl 3) 13-6 24 2009 32 915-20 25 2016 9 26 2016 134 e535-78 27 2015 36 1718-27 28 2014 64 1388-400 29 2019 140 e294-324 30 2006 113 791-8 31 2006 332 73-8 32 The Emerging Risk Factors Collaboration 2010 375 2215-22 33 2006 368 29-36 34 2014 370 1514-23 35 2005 28 2901-7 36 1998 339 229-34 37 2017 38 145-68 38 2005 46 1116-43 39 2010 55 300-5 40 2006 114 2280-7 41 2021 42 3599-726 42 2022 79 e263-421 43 2013 62 1365-72 44 2010 56 1071-8 45 2023 44 368-80 46 Look AHEAD Research Group 2013 369 145-54 47 2016 22 485-91 48 2018 20 1089-95 49 UK Prospective Diabetes Study (UKPDS) Group 1998 352 854-65 50 2005 28 2345-51 51 2005 111 583-90 52 2013 6 395-402 53 2017 41 150-5 54 ADVANCE Collaborative Group 2008 358 2560-72 55 PROactive Investigators 2005 366 1279-89 56 2009 373 2125-35 57 2015 373 2117-28 58 2017 377 644-57 59 2019 380 347-57 60 2017 136 249-59 61 2018 71 2628-39 62 2013 369 1317-26 63 2014 130 1579-88 64 2015 385 2067-76 65 2015 373 232-42 66 2019 321 69-79 67 2015 373 2247-57 68 2016 375 311-22 69 2016 375 1834-44 70 2013 1 9-10 71 2004 164 2273-9 72 2012 367 319-28 73 2017 377 723-32 74 2004 27 699-703 75 2000 101 2271-6 76 2013 10 330-6 77 2018 20 853-72 78 2017 5 333-40 79 2019 381 1995-2008 80 2020 383 1413-24 81 2021 385 1451-61 82 2022 387 1089-98 83 2021 384 117-28 84 2022 400 757-67